MetaCap

China Pharma (CPHI) vs TherapeuticsMD (TXMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TherapeuticsMD (TXMD) has outperformed China Pharma (CPHI) over the past year, losing 3.9% versus a loss of 72.6%. Over five years, TXMD leads with a -94.1% price change compared with -99.8% for CPHI. TherapeuticsMD is the larger company by market cap ($19.8 million vs $18.9 million), about 1.0 times the size.

TherapeuticsMD converts more of its revenue into profit, with a net margin of -18.8% versus -76.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CPHI-72.60%TXMD-3.93%
+430%+167%-97%
Nov 21, 20251 yearNov 20, 2026
CPHI-99.85%TXMD-94.00%
+7%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CPHI versus TXMD key metrics
MetricCPHITXMD
Share price$0.4384$1.71
Market cap$18.86M$19.79M
1-day change-13.00%-5.52%
YTD return-63.77%+4.91%
1-year return-72.60%-3.93%
5-year return-99.84%-94.10%
P/E ratio (TTM)—171.00
Forward P/E—4.89
EPS (TTM)$-0.42$0.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.14M$3.02M
Revenue growth (YoY)-8.49%+71.61%
Net income (latest FY)$-3.19M$-569.00K
Gross margin-3.18%—
Operating margin-78.16%-145.27%
Net margin-76.91%-18.83%
52-week high$19.19$2.95
52-week low$0.38$1.43
Distance from 52-week high-97.72%-42.03%
Average volume1.60M24.50K
Shares outstanding43.02M11.57M
Employees2151
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TXMD has outperformed CPHI by 68.7 percentage points over the past year.
  • TherapeuticsMD is more profitable, keeping -18.8 cents of every revenue dollar as net income versus -76.9 cents for China Pharma.
  • TherapeuticsMD grew revenue faster in its latest fiscal year (+71.61% vs -8.49%).

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

About TherapeuticsMD

TXMD stock →

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

CPHI vs TXMD FAQ

Which is bigger, China Pharma or TherapeuticsMD?

TherapeuticsMD (TXMD) is larger, with a market capitalization of $19.79M compared with $18.86M for China Pharma (CPHI).

Which stock has performed better over the past year, CPHI or TXMD?

TXMD returned -3.93% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.

Are China Pharma and TherapeuticsMD in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons